Dec 2025 $8 M No. 4 $2 to $10 million 98
Nacuity Pharmaceuticals, Inc.: Raise no. 4, Dec 2025 × Investors in this round 98 investors had bought by the notice of Dec 30, 2025: 98 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $8 M of $30 M offered; $22 M still to sell
Smallest investment taken $9,375
What was sold equity, debt, options or other rights to buy securities, securities to be acquired by exercising them, other: Convertible Promissory Notes convertible into preferred stock or common stock, Common Stock Purchase Warrants, Common Stock issued for Warrant Conversion Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $839,335
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Delaware People named in the notice Charles Lieser · Executive Officer David Wohlberg · Executive Officer, Director Halden Conner · Executive Officer, Director Jami Kern · Executive Officer Michael Wall · Executive Officer Benjamin Yerxa · Director Emmett Cunningham, Jr. · Director Gerald Cagle · Director Robin Steele · Director Rusty Kelley · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 120708) · New York, New York Sold in all US states, and outside the US Remarks in the notice On fees: “The figure represents the fee on amount sold to date and that Maxim will also receive placement agent warrants.”Signed by Halden Conner, President and Chief Executive Officer. Source: SEC Form D, newest notice filed Dec 30, 2025. Read the notice at the SEC .
equity, debt, options SEC Mar 2021 $12 M No. 3 $10 to $50 million 144
Nacuity Pharmaceuticals, Inc.: Raise no. 3, Mar 2021 × Investors in this round 144 investors had bought by the notice of Jan 3, 2022: 144 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $12 M of $17 M offered; $6 M still to sell
Smallest investment taken $10,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them, other: Units comprised of Convertible Preferred Shares plus Common Stock Purchase Warrants; Common Stock issued for Warrant conversion; Convertible Preferred Shares issued for exchange of Common Stock Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,444,673
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Charles Lieser · Executive Officer · Chief Financial Officer David Wohlberg · Executive Officer, Director · Secretary Halden Conner · Executive Officer, Director · President and Chief Executive Officer Benjamin Yerxa · Director Gerald Cagle · Director Robert Ruffolo · Director Robin Steel · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 120708) · broker-dealer Clifford Adam Teller (CRD 4631188) · New York, New York Sold in all US states Remarks in the notice On fees: “Commissions include warrants to purchase 716,949 shares of Common Stock at an exercise price of $0.01 per share.”Signed by Halden Conner, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jan 3, 2022. Read the notice at the SEC .
equity, options SEC Jun 2017 $9 M No. 2 $2 to $10 million 125
Nacuity Pharmaceuticals, Inc.: Raise no. 2, Jun 2017 × Investors in this round 125 investors had bought by the notice of Jul 20, 2017: 125 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $9 M of $10 M offered; $1 M still to sell
Smallest investment taken $25,000
What was sold equity, options or other rights to buy securities, other: Units comprised of Convertible Preferred Shares plus Common Stock Purchase Warrants Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $922,700
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Charles Michael Lieser · Executive Officer · Chief Financial Officer G. Michael Wall, Ph.D. · Executive Officer · Vice President of Research and Development William Halden Conner · Executive Officer, Director · President and Chief Executive Officer David J. Wohlberg · Director Dr. Gerald D. Cagle · Director Isaac Michael Blech · Director Richard Michael Chin, M.D. · Director Sanford J. Hillsberg · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Maxim Group LLC (CRD 120708) · broker-dealer Clifford Adam Teller (CRD 4631188) · New York, New York Sold in all US states, and outside the US Remarks in the notice On fees: “Commissions include a Unit Purchase Option to acquire 922,700 Units at an exercise price of $2 per Unit”Signed by Halden Conner, President and Chief Executive Officer. Source: SEC Form D and 1 amendment, newest notice filed Jul 20, 2017. Read the notice at the SEC .
equity, options SEC Nov 2016 $2 M No. 1 Under $2 million 46
Nacuity Pharmaceuticals, Inc.: Raise no. 1, Nov 2016 × Investors in this round 46 investors had bought by the notice of Dec 8, 2016: 46 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $3 M offered; $1 M still to sell
Smallest investment taken $10,000
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice William Halden Conner · Executive Officer, Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Halden Conner, President. Source: SEC Form D, newest notice filed Dec 8, 2016. Read the notice at the SEC .
equity SEC